959-24-0 Usage
Description
Sotalol hydrochloride is a hydrochloride salt that acts as a non-selective antagonist of β-adrenergic receptors (β-ARs) and a class III antiarrhythmic agent. It possesses both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Sotalol hydrochloride is a white crystalline solid, commonly known by the brand names Betapace and Sorine.
Used in Pharmaceutical Industry:
Sotalol hydrochloride is used as a potent beta-adrenergic receptor antagonist for the management of ventricular and supraventricular arrhythmias. It prolongs the action potential and increases the refractory period, helping to maintain normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL).
Used in Analytical Forensic Applications:
Sotalol hydrochloride is used as an analytical reference standard in anti-doping testing, as it has been detected as an adverse analytical finding (AAF) during such tests.
Used in Research:
Sotalol hydrochloride is used as a general research tool for studying the effects of β-adrenergic receptor antagonists on heart rate, blood pressure, and the cardiac functional refractory period (FRP) in various experimental models.
Used in Antibacterial Applications:
Although not explicitly mentioned in the provided materials, sotalol hydrochloride has been reported to possess antibacterial properties, making it potentially useful in the development of new antibiotics or as an additive in existing formulations to enhance their effectiveness.
Biological Activity
A relatively potent pure β adrenergic antagonist, unique in possessing additional class III antiarrhythmic activity. Also available as part of the Mixed Adrenergic Tocriset? .
Clinical Use
Beta-adrenoceptor blocker:
Treatment of life-threatening ventricular
arrhythmias
Prophylaxis of SVT
Veterinary Drugs and Treatments
Sotalol may be useful in the treatment of ventricular tachycardias
and, possibly, supraventricular tachycardias in dogs.
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk ofbradycardia, myocardial depression and AV block
with amiodarone; increased risk of ventricular
arrhythmias with amiodarone, dronedarone,
disopyramide or procainamide - avoid; increased
risk of myocardial depression and bradycardia with
flecainide.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin - avoid; increased
risk of ventricular arrhythmias with delamanid.
Antidepressants: enhanced hypotensive effect with
MAOIs; increased risk of ventricular arrhythmias
with tricyclics; increased risk of ventricular
arrhythmias with citalopram, escitalopram and
venlafaxine - avoid.
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antihypertensives: enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers such as
prazosin.
Antimalarials: increased risk of bradycardia with
mefloquine; avoid with artemether and lumefantrine
and piperaquine with artenimol - increased risk of
ventricular arrhythmias.
Antimuscarinics: increased risk of ventricular
arrhythmias with tolterodine.
Antipsychotics: enhanced hypotensive effect with
phenothiazines; increased risk of ventricular
arrhythmias with amisulpride, droperidol,
haloperidol, phenothiazines, pimozide, risperidone,
sulpiride or zuclopenthixol - avoid with droperidol
and zuclopenthixol.
Antivirals: increased risk of ventricular arrhythmias
with saquinavir or telaprevir - avoid.
Atomoxetine: increased risk of ventricular
arrhythmias.
Calcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem;
hypotension and heart failure possible with
nifedipine and nisoldipine; asystole, severe
hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia
with crizotinib; increased risk of ventricular
arrhythmias with vandetanib - avoid; increased risk
of ventricular arrhythmias with arsenic trioxide,
bosutinib, ceritinib, panobinostat and vandetanib.
Diuretics: enhanced hypotensive effect; increased risk
of ventricular arrhythmias due to hypokalaemia.
Fingolimod: possibly increased risk of bradycardia.
Ivabradine: increased risk of ventricular arrhythmias. Moxisylyte: possible severe postural hypotension.
Ranolazine: avoid concomitant use.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly with
dobutamine.
Metabolism
Metabolism of sotalol is negligible, and it is excreted
unchanged in the urine.
Check Digit Verification of cas no
The CAS Registry Mumber 959-24-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,5 and 9 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 959-24:
(5*9)+(4*5)+(3*9)+(2*2)+(1*4)=100
100 % 10 = 0
So 959-24-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H20N2O3S.ClH/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17;/h4-7,9,12-15H,8H2,1-3H3;1H
959-24-0Relevant articles and documents
Combination of a potassium channel activator and an antiarrhythmic agent
-
, (2008/06/13)
A method for the concomitant treatment of ischemia and arrhythmia in mammalian species which includes administering a combination of a potassium channel opener having little or no effect on action potential duration in the heart and a class III antiarrhythmic compound.
